Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958118 | 0.83 | KDR (0.40) | CYP11B1CYP11B2SMN1; SMN2LMNAHTT | |
| SCHEMBL1960587 | 0.83 | KDM4A (0.45) | FLT1KDRNPC1RAB9AALDH1A1 | |
| SCHEMBL1958365 | 0.83 | L3MBTL1 (0.51) | SMN1; SMN2LMNAHTTPOLBFLT1 | |
| SCHEMBL1960065 | 0.82 | MEN1 (0.49) | SMN1; SMN2LMNAHTTTSHRNPSR1 | |
| SCHEMBL1958985 | 0.82 | POLB (0.50) | LMNAHTTPOLBFLT1KDR | |
| SCHEMBL1958075 | 0.81 | KCNH2 (0.53) | CYP11B1CYP11B2SMN1; SMN2LMNAHTT | |
| SCHEMBL1411948 | 0.80 | HPGDS (0.54) | CYP11B1CYP11B2SMN1; SMN2LMNAPOLB | |
| SCHEMBL1959643 | 0.80 | SMN1; SMN2 (0.52) | CYP11B1CYP11B2SMN1; SMN2LMNAPOLB | |
| SCHEMBL1961795 | 0.80 | KCNH2 (0.42) | LMNAPOLBFLT1KDRALDH1A1 | |
| SCHEMBL1959002 | 0.80 | CYP19A1 (0.51) | CYP11B1CYP11B2SMN1; SMN2FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | claimed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | claimed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | claimed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | claimed |
| EP-2332938-B1 | Viral inhibitors | LEUVEN K U RES & DEV (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | CYP11B1 1458/4885CYP11B2 1903/4885SMN1; SMN2 3179/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | CYP11B1 783/4885CYP11B2 1113/4885SMN1; SMN2 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.